- Active, not recruiting
NCT03327597 : Iceland Screens, Treats or Prevents Multiple Myeloma (iStopMM)
Updated: Sep 22, 2022
Iceland Screens, Treats or Prevents Multiple Myeloma (iStopMM)
Iceland Screens, Treats or Prevents Multiple Myeloma (iStopMM)
This study will assess the benefits and harms of screening for monoclonal gammopathy of undetermined significance (MGUS). The overall and disease-specific mortality will be compared between screened and not screened participants. All individuals registered as inhabitants in Iceland and born in 1975 or earlier have been invited to participate. The hypothesis is that an early detection of multiple myeloma (MM), through follow-up of MGUS, will improve overall survival and decrease complications associated with diagnosis and treatment of MM.
Sponsor
Collaborators
Landspitali University Hospital
Union for International Cancer Control
Icelandic Heart Association
deCODE genetics
Memorial Sloan Kettering Cancer Center
European Research Council
The Icelandic Centre for Research
ClinicalTrials.gov Identifier: NCT03327597
Official Title:Iceland Screens, Treats or Prevents Multiple Myeloma
First Posted : October 31, 2017
Click here for details on ClinicalTrials.gov
Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies
Blood Cancer J; 2021 May
Click here for details
December 11-14, 2021
Georgia World Congress Center - Atlanta, GA
Four Oral Presentations from the International Myeloma Foundation-Supported iStopMM Study to Take Center Stage at 2021 ASH Annual Meeting
LOS ANGELES, Nov. 4, 2021 /PRNewswire/ -- The International Myeloma Foundation (IMF) today announced that data from the IMF-supported iStopMM study will be showcased in four oral presentations at the 63rd American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia, December 11-14. Serum samples from more than 75,000 individuals are enabling the study's Iceland-based research team to shed much-needed light on the early development of myeloma, a cancer of the bone marrow plasma cells, and consider the potential benefits of early screening for MGUS, myeloma's precursor condition.
INTERNATIONAL MYELOMA FOUNDATION:
156 Screening for Monoclonal Gammopathy of Undetermined Significance: A Population-Based Randomized Clinical Trial. First Results from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study
Program: Oral and Poster Abstracts
Type: Oral
Session: 652. Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological: Monoclonal Gammopathies of Determined Significance: What We Have and What We Want
Hematology Disease Topics & Pathways:
Adults, Clinical Trials, Epidemiology, Health Outcomes Research, Clinical Research, Plasma Cell Disorders, Clinically Relevant, Diseases, Lymphoid Malignancies, Study Population
Saturday, December 11, 2021: 1:15 PM
151 Prevalence of Smoldering Multiple Myeloma: Results from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study
Program: Oral and Poster Abstracts
Type: Oral
Session: 652. Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological: Monoclonal Gammopathies of Determined Significance: What We Have and What We Want
Hematology Disease Topics & Pathways:
Adults, Epidemiology, Clinical Research, Plasma Cell Disorders, Diseases, Real World Evidence, Lymphoid Malignancies, Study Population
Saturday, December 11, 2021: 12:00 PM
154 Monoclonal Gammopathy of Undetermined Significance and COVID-19: Results from the Population-Based Iceland Screens Treats or Prevents Multiple Myeloma Study (iStopMM)
Program: Oral and Poster Abstracts
Type: Oral
Session: 652. Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological: Monoclonal Gammopathies of Determined Significance: What We Have and What We Want
Hematology Disease Topics & Pathways:
Adults, Epidemiology, Clinical Research, Plasma Cell Disorders, Clinically Relevant, Diseases, SARS-CoV-2/COVID-19, Real World Evidence, Infectious Diseases, Registries, Lymphoid Malignancies, Study Population
Saturday, December 11, 2021: 12:45 PM
542 Defining New Reference Intervals for Serum Free Light Chains in Individuals with Reduced Kidney Function: Results of the Population- Based on Iceland Screens Treats or Prevents Multiple Myeloma (iStopMM) Study
Program: Oral and Poster Abstracts
Type: Oral
Session: 652. Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological: Reoptimizing Standards and Redefining Approaches
Hematology Disease Topics & Pathways:
Adults, Clinical Research, Plasma Cell Disorders, Clinically Relevant, Diseases, Real World Evidence, Lymphoid Malignancies, Study Population
Sunday, December 12, 2021: 4:45 PM
2645 Monitoring of Circulating Tumor Plasma Cells in Patients with Precursor Conditions of Multiple Myeloma: Data from the Prospective Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study
Program: Oral and Poster Abstracts
Session: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster II
Hematology Disease Topics & Pathways:
Translational Research, Clinical Research, Plasma Cell Disorders, Clinically Relevant, Diseases, Lymphoid Malignancies
Sunday, December 12, 2021, 6:00 PM-8:00 PM
1618 Estimating Selection Bias in Previous Monoclonal Gammopathy of Undetermined Significance Research – the Importance of Screening: Results from the Population-Based Screening Study Iceland Screens, Treats or Prevents Multiple Myeloma (iStopMM)
Program: Oral and Poster Abstracts
Session: 652. Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological: Poster I
Hematology Disease Topics & Pathways:
Adults, Epidemiology, Clinical Research, Plasma Cell Disorders, Diseases, Lymphoid Malignancies
Saturday, December 11, 2021, 5:30 PM-7:30 PM
Europe
Iceland
University of Iceland
Reykjavík, Iceland